Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.45 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470555 | 0.90 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL1470556 | 0.90 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL556530 | 0.90 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL565485 | 0.90 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL15765888 | 0.90 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL146562 | 0.90 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3MEN1DRD2 | |
| SCHEMBL10054587 | 0.90 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3MEN1DRD2 | |
| SCHEMBL122155 | 0.90 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3MEN1DRD2 | |
| SCHEMBL13349121 | 0.89 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL27686752 | 0.89 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3SCN4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2014164543-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | KMT2A 6/4885L3MBTL1 619/4885KCNA3 3465/4885 |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | KMT2A 6/4885L3MBTL1 603/4885KCNA3 3393/4885 |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | KMT2A 11/4885L3MBTL1 1147/4885KCNA3 3605/4885 |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | KMT2A 7/4885L3MBTL1 1021/4885KCNA3 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.